Prostate Cancer Radioligand Therapy
IF 3
Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
引用次数: 0
前列腺癌放射性配体疗法：β标记放射性药物。
前列腺癌是全球男性最常见的恶性肿瘤，在美国每年新增病例约 174,650 例，是仅次于肺癌的第二大癌症死因，每年有 31,620 人死于前列腺癌。没有转移扩散的前列腺癌患者的 5 年生存率接近 100%，而有远处转移的患者的 5 年生存率约为 30%。初步诊断和评估基于前列腺特异性抗原（PSA）水平、格里森评分（通过前列腺活检得出）以及先进的成像模式，包括前列腺磁共振成像和 PSMA-PET/计算机断层扫描（适用于具有高危特征的患者）。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
PET Clinics
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
5.70
自引率
3.80%
发文量
78
期刊介绍：
As the clinical applications of positron emission tomography (PET) increase, the new PET Clinics brings together the combined expertise of leading authorities in the field to provide you incisive clinical reviews on advances in the use of PET and combined PET/CT. Published quarterly, PET Clinics provides concise, practical guidance on the clinical issues you face every day. It examines PET is effectiveness in cancer diagnosis and staging, as well as exploring PET is usefulness in the areas of dementia, myocardial viability, and other conditions. Full-color images featured throughout. Topics covered include Breast Cancer, Alzheimer is Disease and Dementia, Lymphoma, Lung Cancer, Cardiology, Pediatric Applications, Infection and Inflammation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
